Our favorite blog post series is “The Authors’ Own Words“, where we ask authors to describe their impressions regarding the implications of their accepted work, how their findings will change practice, and what is noteworthy about the work. We enjoy allowing a space for authors to express their thoughts on their work and for readers to gain further insight.

We are eager to start a new blog post series “Our Readers Chime In” – which is similar to “The Authors’ Own Words” but allows our readers to give their own thoughts and insight into our manuscripts. Readers can let us know what they found interesting, what they’ve incorporated into their own practice, reactions, and more. Readers are welcome to give a “chime” to any manuscript we’ve published over the many years. The chime will be posted here on our blog!

If you are interested in chiming in, email a paragraph or two and the article you are responding to our team managing.editor.saj@gmail.com or by shooting us a DM on our twitter to submit.

The Authors’ Own Words: We ask authors to describe their impressions regarding the implications of their accepted work, how their findings will change practice, and what is noteworthy about the work.

Advanced Practice Nurses: Increasing Access to Opioid Treatment by Expanding the Pool of Qualified Buprenorphine Prescribers

Matthew Tierney, MS, PMHNP-BC; Deborah S. Finnell, DNS, PMHNP-BC, CARN-AP, FAAN; Madeline A. Naegle, PhD, CNS-PMH, BC, FAAN; Colleen LaBelle, BSN, RN-BC, CARN; & Adam J. Gordon, MD, MPH

Volume 36, 2015 – Issue 4

“This editorial is noteworthy for appealing to a broad audience to promote Advanced Practice Registered Nurses (APRNs) to prescribe buprenorphine to treat opioid use disorders.  This significant change in practice would require a change to current federal law that currently grants only physicians the authority to prescribe buprenorphine for opioid use disorder. The authors join other stakeholders, including professional organizations and communities throughout the US represented by numerous senators, by calling for APRNs to join the insufficient number of physicians now prescribing buprenophine in order to increase access to care in the context of ever-increasing morbidities and mortality associated with opioid use. APRNs are already involved in all other aspects of care for patients with opioid use disorder, and are known to be safe providers who are interested in providing this evidence-based treatment.”

Follow us on twitter to stay up to date with SAj, upcoming publications, and more!

The Authors’ Own Words: We ask authors to describe their impressions regarding the implications of their accepted work, how their findings will change practice, and what is noteworthy about the work.

Do Alcohol Advertisements for Brands Popular among Underage Drinkers Have Greater Appeal among Youth and Young Adults?

Michael Siegel, MD, MPH; William DeJong, PhD; Daryl Cioffi, BA; Lucero Leon-Chi, BS; Timothy S. Naimi, MD, MPH; Alisa A. Padon, PhD; David H. Jernigan, PhD; & Ziming Xuan, ScD, MS, MA

Volume 37, 2016 – Issue 1: Includes Special Section: “From Education to Implementation: Addressing the Opioid Misuse Epidemic”

“This study is the first to compare the extent of youth appeal of alcohol advertisements for brands popular among underage drinkers vs. brands unpopular among underage drinkers. We found that the advertisements for more popular brands were significantly more likely to be perceived as appealing to youth. This research is important for two reasons. First, it informs the debate about whether alcohol companies are targeting youth with their advertising. If youth-oriented brands are more likely to contain youth-oriented content, this could be an indication that the companies are preferentially trying to reach underage youth. Second, the research may help shed light on the debate about whether alcohol advertising is effective in influencing youth drinking behavior. If brands whose alcohol ads appeal more heavily to youth turn out to be the same brands that are popular among youth, this could be an indication that the advertising is influencing youth brand choices.” Do Alcohol Advertisements for Brands Popular among Underage Drinkers Have Greater Appeal among Youth and Young Adults?”

Follow us on twitter to stay up to date with SAj, upcoming publications, and more!

We hope that you enjoy revisiting past volumes and issues as much as we do! The past week we have been taken a look at SAj Volume 37, Issue 2 published 4 years ago in 2016.

The most viewed manuscript in this issue was:

Potential medications for the treatment of alcohol use disorder: An evaluation of clinical efficacy and safety

Raye Z. Litten, PhD; Bonnie B. Wilford, MS; Daniel E. Falk, PhD; Megan L. Ryan, MBA; & Joanne B. Fertig, PhD

With 1,402 views…and counting!

The Authors’ Own Words: We ask authors to describe their impressions regarding the implications of their accepted work, how their findings will change practice, and what is noteworthy about the work.

A delayed injection-site reaction in a patient receiving extended-release naltrexone

Keith Ahamad, MD; P. Todd Korthuis, MD, MPH; Paula J. Lum, MD; Cheyenne Johnson, RN; & Evan Wood, MD, PhD

Volume 37, 2016 – Issue 2

“Extended release naltrexone has been shown to be effective in treating alcohol use disorder and helps deal with adherence issues. This case highlights the importance of monitoring patients for injections site reactions, which may not be related to the more commonly reported infection related cases.”

Follow us on twitter to stay up to date with SAj, upcoming publications, and more!